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High-throughput ‘omics’ technologies that generate molecular profiles for biospecimens have been extensively
used in preclinical studies to reveal molecular subtypes and elucidate the biological mechanisms of disease, and in
retrospective studies on clinical specimens to develop mathematical models to predict clinical endpoints.
Nevertheless, the translation of these technologies into clinical tests that are useful for guiding management
decisions for patients has been relatively slow. It can be difficult to determine when the body of evidence for an
omics-based test is sufficiently comprehensive and reliable to support claims that it is ready for clinical use, or even
that it is ready for definitive evaluation in a clinical trial in which it may be used to direct patient therapy. Reasons
for this difficulty include the exploratory and retrospective nature of many of these studies, the complexity of these
assays and their application to clinical specimens, and the many potential pitfalls inherent in the development of
mathematical predictor models from the very high-dimensional data generated by these omics technologies. Here
we present a checklist of criteria to consider when evaluating the body of evidence supporting the clinical use of a
predictor to guide patient therapy. Included are issues pertaining to specimen and assay requirements, the
soundness of the process for developing predictor models, expectations regarding clinical study design and
conduct, and attention to regulatory, ethical, and legal issues. The proposed checklist should serve as a useful guide
to investigators preparing proposals for studies involving the use of omics-based tests. The US National Cancer
Institute plans to refer to these guidelines for review of proposals for studies involving omics tests, and it is hoped
that other sponsors will adopt the checklist as well.
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High-throughput ‘omics’ technologies may allow more in-
formative characterization of disease to better predict both
an individual patient’s clinical course and the degree of
benefit he or she may derive from new and existing the-
rapies. The potential for detailed characterization of dis-
ease has been met with particularly great enthusiasm in
oncology, where the heterogeneous character of malignant
diseases has long presented challenges. However, despite* Correspondence: mcshanel@ctep.nci.nih.gov
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reproduction in any medium, provided the or
2013the widespread use of these technologies in both preclin-
ical and retrospective studies, it has proven more difficult
than expected to translate their promise into clinically use-
ful tests that can be used to guide management decisions.
This paper focuses on molecular tests derived from
high-throughput omics assays (‘omics-based tests’ or sim-
ply ‘omics tests’) as defined in the Institute of Medicine
(IOM) report Evolution of Translational Omics [1]. An
IOM committee that was convened to review omics-based
tests for predicting patient outcomes in clinical trials de-
fines ‘omics’ as the study of related sets of biological mole-
cules in a comprehensive fashion. Examples of omics
disciplines include genomics, transcriptomics, proteomics,
metabolomics, and epigenomics. Further, the IOM com-
mittee defined an omics-based test as ‘an assay composedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interpreted by a fully specified computational model to
produce a clinically actionable result’ [1].
A distinguishing characteristic of the omics tests
discussed here is that computational methods are ap-
plied to the high-dimensional data to build mathematical
models, often from a subset of the measured variables
that have been identified through data-driven selection.
This is in contrast to molecular tests based on pre-
specified, biologically driven variables, such as muta-
tions in genes targeted by a new therapeutic agent,
which might be used to screen patients for eligibility
for a clinical trial. Although these biologically driven
tests must be based on assays with appropriate analy-
tical performance, they are not subject to all of the
same pitfalls that are inherent in omics tests involving
complex computational models, so they are not the
main focus of this paper.
The development path from high-throughput omics
technology to a clinical-grade omics test requires rigor-
ous attention to criteria including the following:
 Availability and quality of appropriate clinical
specimens
 Requirements for the analytical performance of the
omics assay
 Methods for omics data pre-processing
 Development of the mathematical predictor model
and assessment of its performance
 Clinical interpretation of the test result
 Design of the clinical trial
 Ethical, legal, and regulatory issues
Given the rich data emerging from cancer genomics
research, it might seem surprising that relatively few
omics tests have successfully navigated this path to clin-
ical use. In some cases, the use of omics tests in clinical
trials, or their promotion for routine clinical use, has
been premature [1].
There are many reasons for the paucity of omics tests
that are able to provide patients and clinicians with in-
formation that is useful in the assessment and treatment
of disease. They include difficulty in obtaining a suffi-
cient number of acceptable-quality biospecimens with
the desired clinical and pathological characteristics, as
well as technical challenges in the development and im-
plementation of assays that can be successfully applied
to the available types of clinical specimens. Optimal ana-
lytical performance and reproducibility of an omics assay
may be difficult to achieve, or the assay may lack robust-
ness to ancillary pre-analytical influences on specimens.
Translation has also been hampered by the difficulties in
properly evaluating the accumulated body of evidence
for an omics test by the time there is interest in itsdefinitive evaluation in a clinical trial. Omics studies are
often not reported in sufficient detail to allow assess-
ment of the rigor with which the test was developed or
evaluated. Adequate data and computer code are not al-
ways made available to allow understanding of the
methods used in the development of the test or to facili-
tate independent replication of the results. Subtle flaws
in statistical approaches for developing or assessing the
performance of mathematical models may go un-
detected. It is essential to consider all of these issues be-
fore launching into a clinical study using an omics test
in a way that might influence the clinical management
of patients [2].
Presented here are criteria that should be addressed to
determine the readiness of an omics test for use in a
prospective clinical trial or study. These criteria apply to
tests derived from high-dimensional data generated by
any type of omics technology when those tests are being
proposed for use in a study in a way that will influence
patient care. The criteria address not only the strength
of evidence in support of an omics test but also the prac-
tical issues that must be considered before using the test
in a clinical setting. Commentary accompanies each cri-
terion to provide the rationale for and more specific de-
tails about the type of information requested. The
complete set of criteria is assembled into a checklist,
which is shown in Table 1.
This checklist applies to any clinical trial involving in-
vestigational use of an omics test that will influence the
clinical management of patients in the trial, for example,
the selection of therapy. In situations where an omics
test will be evaluated retrospectively on valuable non-
renewable specimens collected from patients who were
prospectively enrolled in clinical studies, many of the
checklist criteria are still applicable and the checklist can
serve as a useful guide in judging the quality of the pre-
dictor development process and the strength and reli-
ability of the evidence.
This paper is intended as an annotated companion to
the short version of these guidelines published elsewhere
[3]. Whereas that brief article provides a quick overview
of the checklist, background on its development, and
discussion of the context in which it is intended to be
used, this longer paper elucidates the rationale under-
lying the development of the criteria in greater detail.
These are general guidelines, and it is recognized that
there may be nuances in how they are applied to a particu-
lar omics test and clinical setting. The development of
omics tests typically proceeds through a series of studies,
and it may not be possible to address all of these criteria in
early developmental studies. Ideally, investigators should
consult this checklist during the research planning and test
development phases so that critical evidence is systematic-
ally acquired and reported and, by the time the test is ready
Table 1 Criteria for the use of omics-based predictors in National Cancer Institute-supported clinical trials
Domain Criteria
Specimen issues 1. Establish methods for specimen collection and processing and appropriate storage
conditions to ensure the suitability of specimens for use with the omics test.
2. Establish criteria for screening out inadequate or poor-quality specimens or analytes
isolated from those specimens before performing assays.
3. Specify the minimum amount of specimen required.
4. Determine the feasibility of obtaining specimens that will yield the quantity and
quality of isolated cells or analytes needed for successful assay performance in
clinical settings.
Assay issues 5. Review all available information about the standard operating procedures (SOPs) used
by the laboratories that performed the omics assays in the developmental studies,
including information on technical protocol, reagents, analytical platform, assay scoring, and
reporting method, to evaluate the comparability of the current assay to earlier versions and to
establish the point at which all aspects of the omics test were definitively locked down
for final validation.
6. Establish a detailed SOP to conduct the assay, including technical protocol,
instrumentation, reagents, scoring and reporting methods, calibrators and analytical
standards, and controls.
7. Establish acceptability criteria for the quality of assay batches and for results from
individual specimens.
8. Validate assay performance by using established analytical metrics such as accuracy,
precision, coefficient of variation, sensitivity, specificity, linear range, limit of detection,
and limit of quantification, as applicable.
9. Establish acceptable reproducibility among technicians and participating laboratories
and develop a quality assurance plan to ensure adherence to a detailed SOP and
maintain reproducibility of test results during the clinical trial.
10. Establish a turnaround time for test results that is within acceptable limits for use
in real-time clinical settings.
Model development, specification, and
preliminary performance evaluation
11. Evaluate data used in developing and validating the predictor model to check for
accuracy, completeness, and outliers. Perform retrospective verification of the data quality
if necessary.
12. Assess the developmental data sets for technical artifacts (for example, effects of assay
batch, specimen handling, assay instrument or platform, reagent, or operator), focusing
particular attention on whether any artifacts could potentially influence the observed
association between the omics profiles and clinical outcomes.
13. Evaluate the appropriateness of the statistical methods used to build the predictor
model and to assess its performance.
14. Establish that the predictor algorithm, including all data pre-processing steps, cutpoints
applied to continuous variables (if any), and methods for assigning confidence measures for
predictions, are completely locked down (that is, fully specified) and identical to prior
versions for which performance claims were made.
15. Document sources of variation that affect the reproducibility of the final predictions,
and provide an estimate of the overall variability along with verification that the prediction
algorithm can be applied to one case at a time.
16. Summarize the expected distribution of predictions in the patient population to which
the predictor will be applied, including the distribution of any confidence metrics associated
with the predictions.
17. Review any studies reporting evaluations of the predictor’s performance to determine
their relevance for the setting in which the predictor is being proposed for clinical use.
18. Evaluate whether clinical validations of the predictor were analytically and statistically
rigorous and unequivocally blinded.
19. Search public sources, including literature and citation databases, journal correspondence,
and retraction notices, to determine whether any questions have been raised about the data
or methods used to develop the predictor or assess its performance, and ensure that all
questions have been adequately addressed.
Clinical trial design 20. Provide a clear statement of the target patient population and intended clinical use of
the predictor and ensure that the expected clinical benefit is sufficiently large to support its
clinical utility.
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Table 1 Criteria for the use of omics-based predictors in National Cancer Institute-supported clinical trials (Continued)
21. Determine whether the clinical utility of the omics test can be evaluated by
using stored specimens from a completed clinical trial (that is, a prospective–retrospective study).
22. If a new prospective clinical trial will be required, evaluate which aspects of the
proposed predictor have undergone sufficiently rigorous validation to allow treatment
decisions to be influenced by predictor results; where treatment assignments are
randomized, provide justification for equipoise.
23. Develop a clinical trial protocol that contains clearly stated objectives and methods
and an analysis plan that includes justification of sample size; lock down and fully
document all aspects of the omics test and establish analytical validation of the predictor.
24. Establish a secure clinical database so that links among clinical data, omics data, and
predictor results remain appropriately blinded, under the control of the study statistician.
25. Include in the protocol the names of the primary individuals who are responsible for
each aspect of the study.
Ethical, legal, and regulatory issues 26. Establish communication with the individuals, offices, and agencies that will oversee
the ethical, legal, and regulatory issues that are relevant to the conduct of the trial.
27. Ensure that the informed consent documents to be signed by study participants
accurately describe the risks and potential benefits associated with use of the omics
test and include provisions for banking of specimens, particularly to allow for ‘bridging
studies’ to validate new or improved assays.
28. Address any intellectual property issues regarding the use of the specimens, biomarkers, assays, and
computer software used for calculation of the predictor.
29. Ensure that the omics test is performed in a Clinical Laboratory Improvement
Amendments-certified laboratory if the results will be used to determine treatment or
will be reported to the patient or the patient’s physician at any time, even after the trial
has ended or the patient is no longer participating in the study.
30. Ensure that appropriate regulatory approvals have been obtained for investigational
use of the omics test. If a prospective trial is planned in which the test will guide treatment,
consider a pre-submission consultation with the US Food and Drug Administration.
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evidence to comprehensively address the criteria has been
obtained. It is hoped that researchers will find this checklist
useful as they prepare background material for research
proposals and clinical trial protocols.
Specimen issues
1. Establish methods for specimen collection and
processing and appropriate storage conditions to
ensure the suitability of specimens for use with the
omics test.
Numerous factors can alter a specimen’s molecular char-
acteristics and influence the usability of a specimen, or
analytes isolated from a specimen, for an omics assay
[4-10]. The exquisite sensitivity of omics technologies to
subtle biologic variations also implies that some of these
technologies can be easily influenced by factors encoun-
tered in specimen collection, processing, and storage. Spec-
imens or isolated analytes may become degraded or their
omics profiles altered in unexpected ways. The entire life
cycle of the specimen should be considered, beginning with
the condition of the host when the specimen is first ac-
quired (for example, patient has been fasting or is anesthe-
tized) and including the procedure by which it is acquired(for example, surgical excision, core needle biopsy,
venipuncture, bone marrow aspiration), the processing
method (for example, snap-frozen in liquid nitrogen), use
of stabilizers and preservatives (for example, ethylenedi-
amine tetraacetate, neutral buffered formalin), and storage
method (for example, -80°C, room temperature, vacuum
sealed). Investigators should review all available data on
these factors for the specimens used in the developmental
studies for the omics test or should conduct further investi-
gations to examine the influence of such factors on the
omics test’s performance. It is important to document that
the omics test will perform satisfactorily under the range of
conditions in which the specimens will be obtained and
stored in typical clinical settings; alternatively, more re-
strictive requirements for specimen collection, processing,
and storage should be clearly specified before the test is
used in a clinical trial or other clinical validation study.
2. Establish criteria for screening out inadequate or
poor-quality specimens or analytes isolated from
those specimens before performing assays.
In many situations it will be impossible to identify and
record all of the factors that might influence the quality
of specimens or isolated analytes. It may be necessary to
make a decision about the acceptability of a specimen
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specimen in hand. This requires that criteria for specimen
quality be carefully specified in order to qualify a specimen
or its isolated analytes as suitable for assay by the omics
test. Such criteria might also be developed and used in
addition to specifications on specimen acquisition, process-
ing, and storage. Appropriate criteria will depend on the
specimen type and the particular assay platform to be used.
For omics assays based on RNA, the RNA Integrity Num-
ber (RIN; Agilent Technologies) is an example of such a
quality metric [11], although thresholds for acceptable qual-
ity may be context dependent. The RIN is generally consid-
ered a valid quality criterion for RNA extracted from frozen
specimens, but there is no consensus on its value for RNA
extracted from formalin-fixed, paraffin-embedded speci-
mens. Amount of DNA fragmentation might not be an
important factor for immunohistochemical or fluorescence
in situ hybridization assays applied to formalin-fixed,
paraffin-embedded specimens, but omics assays might not
perform well on highly fragmented DNA. In such cases, cri-
teria assessing the extent of DNA fragmentation may be an
essential component of the quality screen. A disadvantage
of basing decisions for specimen acceptability only on the
measurable characteristics of the specimen or isolated
analytes is that this approach relies on those characteristics
to capture the relevant influences of prior conditions.
3. Specify the minimum amount of specimen required.
The performance of an omics assay may be closely re-
lated to the amount (mass or volume) of specimen avail-
able or to the purity of the target material. In many cases,
the composition of a specimen is a heterogeneous mix of
cells of interest. For example, a surgical tissue specimen
from a patient with cancer may consist of tumor cells
admixed with necrotic tissue, normal epithelial cells, cir-
culating blood cells, and stromal cells, and the presence of
the non-tumor cells may dilute the target to be measured
and cause false-negative assay results. Sometimes analyte
enrichment techniques such as laser capture microdissec-
tion are used to enrich for cells of interest (for example,
tumor cells) from whole-tissue specimens. Another com-
mon problem is extensive contamination of bone marrow
aspirates with blood cells. Often, there may be a trade-off
between specimen quality and quantity. For example, a
partially degraded DNA sample might still be acceptable if
the total amount is sufficient to contain an adequate num-
ber of high-quality DNA molecules. An extensive analysis
of the suitability of DNA, RNA, and protein extracted
from core needle biopsies of kidney cancer provides an ex-
ample of how one might assess the quantity and quality of
analytes that could be isolated from a particular type of
specimen [12]. Criteria should be established not only for
the starting amount of specimen, but also for the percentpurity of the target cells or intact analyte of interest. These
evaluations should be performed by individuals with ap-
propriate expertise in histopathology.
4. Determine the feasibility of obtaining specimens that
will yield the quantity and quality of isolated cells or
analytes needed for successful assay performance in
clinical settings.
Many omics tests are developed with retrospective
collections of specimens that might have already been
pre-selected to be of sufficient quality and quantity and
thus may not be representative of the specimens that
are likely to be obtained in the intended-use clinical
setting. It might not be known whether this pre-
selection has occurred. There may be no record of the
number of patients for whom specimen collection was
initially attempted or of the number of attempts that
were made per patient until those attempts were either
successful or aborted. Some specimens might have been
previously collected in specialized research settings in
which there were adequate expertise and resources to
successfully execute the collections. Patients treated in
the context of research studies may be more accepting
of specimen collection and more tolerant of potentially
invasive specimen collection procedures, leading to
greater success in specimen collection in these settings
than might be expected in routine clinical settings. To
evaluate the feasibility of collecting the needed quantity
and quality of specimens in a multicenter clinical trial
or a routine clinical setting, it may be necessary to con-
duct a preliminary feasibility study in more realistic
clinical settings. It is important to establish that the
omics test is sufficiently robust and will perform ac-
ceptably for specimens likely to be encountered in clin-
ical practice.
Assay issues
5. Review all available information about the standard
operating procedures (SOPs) used by the laboratories
that performed the omics assays in the developmental
studies, including information on technical protocol,
reagents, analytical platform, assay scoring, and
reporting method, to evaluate the comparability of the
current assay to earlier versions and to establish the
point at which all aspects of the omics test were
definitively locked down for final validation.
The value of critically examining the history of an
assay’s development before proceeding to a clinical trial
is often underappreciated. Research laboratories in par-
ticular may modify their assay methods over time to im-
prove assay performance or adapt to changing costs or
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Before an omics test is considered for use in a clinical
trial, the assay methods used and the data gathered in
the developmental stages should be carefully reviewed to
determine whether the version of the assay underlying
the omics test being proposed for the trial can be expected
to generate data comparable to those generated by the
former version(s) of the assay. This can be a particular
challenge when using omics tests utilizing commercially
available microarrays or other rapidly evolving technolo-
gies. This assessment should include not only the primary
(‘raw’) data generated by the assay but also any scoring
method or interpretation rule (for example, positive versus
negative) that is to be applied. If data generated in mul-
tiple laboratories were used in the development process, it
should also be determined whether the different laborator-
ies generated comparable data.
A fully specified assay method (see Criterion 6) is one of
the critical aspects of a locked-down omics test. Additional
requirements for a locked-down test include specific speci-
men requirements (see Criteria 1 to 3), detailed data pre-
processing instructions, and a fully specified computational
model for prediction (see Criteria 14 and 23). Before an
omics test is used in a trial, it should have been validated in
a pre-specified, locked-down form. If changes have been
made to any aspect of the test, it must be established that
the modified test produces results that are highly compar-
able to those of a version that has been previously validated
clinically in locked-down form.
6. Establish a detailed SOP to conduct the assay,
including technical protocol, instrumentation,
reagents, scoring and reporting methods, calibrators
and analytical standards, and controls.
The assay protocol should be sufficiently detailed to
ensure its reproducibility. Elements in the SOP should
be specific to minimize variation in the result when the
assay is performed at different times, in different labora-
tories (if more than one laboratory will run the test), and
by different technicians. The SOP should include not
only the technical steps for conducting the assay, but
also the instrumentation, reagents, scoring and reporting
method, types of calibrators and analytical standards,
controls, and quality control procedures for monitoring
assay performance to ensure intra- and inter-laboratory
reproducibility (see Criterion 7). To avoid ambiguity in
usage of the terms ‘calibrators’, ‘standard’, and ‘controls’,
they are defined here as follows:
 A calibrator is a sample engineered to produce a
specific value for a particular analyte and is used in
the development of a calibration curve to
standardize assay values from run to run. An analytical standard is a sample that has been
extensively characterized and is expected to
produce a consistent assay result in repeated
assays over time.
 A control is a biological specimen that is available in
sufficient quantity to include in multiple assay
batches to monitor assay performance for potential
drift; or a biological specimen that is expected to
produce an unequivocally negative (negative control)
or positive (positive control) result.
The SOP should be developed with attention to the
expected context of use in the community after the con-
clusion of the clinical trial or confirmatory validation
study. Parameters that are specific to reliability and
feasibility for clinical use, like maximum turnaround
time, should also be specified (see Criterion 10). To en-
sure that the test results are clearly transmitted for ap-
propriate clinical interpretation, the SOP should also
exactly specify the format in which the output of the
assay will be reported.
7. Establish acceptability criteria for the quality of assay
batches and for results from individual specimens.
Unexpected technical problems can occur during the
course of an assay, producing aberrant results for individ-
ual samples or entire assay batches. A quality monitoring
system should be in place to detect these problems. For ex-
ample, a comprehensive set of performance metrics has
been proposed for liquid chromatography–tandem mass
spectrometry systems in proteomics analyses [13]. The ac-
ceptability criteria may focus on bias or precision or both.
Control samples, analytical standards, and blinded replicate
samples, when used consistently, can be effective tools for
detecting assay problems and ensuring consistency of re-
sults [14-16]. The recommended types of controls, analyt-
ical standards, and replicates, along with the criteria used
to determine acceptability of assay results, should be speci-
fied in the assay protocol. Routinely measuring individual
samples in duplicate or triplicate can also be helpful to
identify unreliable readings, though it might not be helpful
to detect biased readings. Lastly, these procedures should
also include replicate analyses of controls and standards
over time to ensure the temporal stability of the omics as-
says and isolated analytes under the specified conditions of
storage. This issue is of particular importance in the con-
text of prospective trials in which patient accrual and sam-
ple collection and analysis will occur over a protracted
period of time. The use of these types of quality assurance
and quality control procedures will increase confidence in
the assay results and help to guard against serious assay
failures that could affect patient care directed by the test
results.
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analytical metrics such as accuracy, precision,
coefficient of variation, sensitivity, specificity, linear
range, limit of detection, and limit of quantification,
as applicable.
Before an omics test is used in a clinical trial, the analyt-
ical performance of the assay should be evaluated to estab-
lish the assay’s analytical validity. This evaluation should
examine performance metrics, such as accuracy, precision,
coefficient of variation, sensitivity, specificity, linear range,
limit of detection, and limit of quantitation, as applicable for
the particular test under study. A study reported by Tabb et
al. [17] provides examples of the types of repeatability and
reproducibility assessments that could be made in prote-
omic identifications by liquid chromatography–tandem
mass spectrometry. A number of helpful guidance docu-
ments and templates that outline best practices for charac-
terizing assay analytical performance are available [18-27].
If individual biomarker measurements are combined (for
example, as a weighted average), it may be useful to under-
stand the analytical performance characteristics of the indi-
vidual biomarker measurements that enter into the omics
prediction model, particularly in the model development
stage. However, assessment of the analytical characteristics
of the final result produced by the omics test is of primary
importance as the test is moved into use in a clinical trial.
The bias or imprecision in the final result will have a direct
impact on the patient care that is guided by the test. For
example, a genomics test might produce a continuous risk
score, calculated as a linear combination of multiple bio-
marker measurements. The reproducibility of the final risk
score generated by such a linear predictor will depend on
the bias and precision of the measurements of the individ-
ual biomarkers and the weight given to each biomarker in
the risk score. A cutpoint may be applied to the risk score
for translation into a clinical classification. The reproduci-
bility of the final clinical classification will then depend on
the reliability of the risk score and the proportion of the
risk scores that cluster near the cutpoint. Higher variability
can be tolerated in a risk score when it is far away from a
cutpoint, because the final clinical classification is unlikely
to change due to inaccuracy in the risk score. Special con-
siderations apply to prediction models that require com-
plex iterative or stochastic calculations for evaluation, in
contrast to the simple setting of the linear risk score just
discussed (see Criteria 15 and 16).
Assessment of the analytical performance of an omics
test should be carried out with a set of clinical speci-
mens that reflect the expected range of combinations of
component omics variable values. The clinical specimens
used in analytical validation studies should be represen-
tative of the types of specimens anticipated in the
targeted clinical setting, and the patients from whomthose specimens are collected should cover a spectrum
similar to that of patients for whom the test is intended.
9. Establish acceptable reproducibility among
technicians and participating laboratories and
develop a quality assurance plan to ensure
adherence to a detailed SOP and maintain
reproducibility of test results during the clinical trial.
Unexpectedly large differences in assay results can be
caused by the particular technician performing any step of
an assay, as well as by differences in environments or
standard practices across laboratories or clinical sites.
Strict adherence to detailed SOPs for specimen collection,
processing, and handling and for assay procedures can
substantially reduce the amount of variation in omics test
results due to these factors; however, it may not be pos-
sible to completely eliminate this variation [28-31]. Pre-
liminary data should be presented to establish acceptable
reproducibility across technicians, analytical instruments
or platforms, laboratories, and clinical sites. Because la-
boratory and clinical staff and environments can change
and new clinical sites may be added over time, it is also
important to have in place quality assurance programs
and quality monitoring processes to ensure that compar-
ability is maintained throughout the course of a validation
study or clinical trial. Recommended procedures might in-
clude initial training and qualification of staff, periodic re-
fresher training sessions, and use of blinded replicate or
control specimens to directly assess the comparability of
assay results over time and across laboratories. If the test
is to be used to determine treatment, it must be performed
in a Clinical Laboratory Improvement Amendments
(CLIA)-certified laboratory. A CLIA-certified laboratory
would typically have these procedures already in place, al-
though CLIA certification would not ensure comparability
across laboratories when more than one laboratory is in-
volved in performing assays for a study.
10. Establish a turnaround time for test results that is
within acceptable limits for use in real-time clinical
settings.
For an omics-based test to be useful in clinical practice,
it must be feasible to collect and process the required spe-
cimen, complete the assay, generate and confirm the valid-
ity of the primary data, compute the predictions, and have
the result available within an acceptable time frame with-
out substantially delaying the usual timing of clinical deci-
sions regarding treatment or other follow-up care. Because
many omics-based tests are developed and preliminarily
validated on retrospective specimen collections, in some
cases there is no prior opportunity to assess the feasibility
of using the test in real time. Feasibility studies should be
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the necessary infrastructure and resources will be in place
to collect and process the required specimens according to
the specified methods, that there will be sufficient capacity
in the laboratories performing the assays, and that it will
be possible to achieve timely data submission and process-
ing to generate the predictions for individual patients in
the trial.
Model development, specification, and preliminary
performance evaluation
11. Evaluate data used in developing and validating the
predictor model to check for accuracy,
completeness, and outliers. Perform retrospective
verification of the data quality if necessary.
It is strongly advised that a critical and independent
evaluation be conducted of the quality of the data used to
develop and preliminarily validate an omics predictor. Un-
like data for clinical trials, which are typically collected
under standardized and carefully quality-controlled condi-
tions, in many cases data used to develop predictors are
based on assays conducted on banked clinical specimens
for which clinical and pathologic data may have been as-
sembled from retrospective record reviews. Both the omics
assay data and the clinical and pathologic data used in the
studies should be carefully reviewed for any evidence of er-
rors, inconsistencies, or biases resulting from careless or
incomplete data collection and clinical annotation.
In some cases the omics assays might have been
conducted by others and only the omics data, and not the
specimens, are available. In these situations there may be
little information available about the quality of the speci-
mens or assay procedures used. Quality metrics have been
proposed for data from some types of omics assays
[32-35], and these can be helpful to identify potential
problems. Quality assessments should be performed on
the primary omics data from original sources, if available,
as well as on any pre-processed data to confirm that no er-
rors were introduced during data handling and processing.
Some omics data problems can be identified by use of
simple descriptive statistics. Unusually high correlation be-
tween molecular profiles of two different specimens may
indicate an unintended duplication of specimen labels.
When analyzing data merged from several different stud-
ies, one should always assess for high correlations between
specimens that could occur if there is overlap in the pa-
tients whose specimens were examined in the different
studies. For nucleic acid-based assays, cross-contamination
of specimens can occur and distort genetic variant profiles.
It is worthwhile to conduct these preliminary data analyses
to allow for identification and removal of problematic data
and increase confidence in the data’s reliability.Clinical and pathologic data should be examined for evi-
dence of internal inconsistencies (for example, recurrence
date after date of death), extreme observations (for ex-
ample, 9-year-old patient with breast cancer) or implaus-
ible data combinations (for example, male patient with
ovarian cancer). Extreme observations or unusual data
combinations can have a large influence on the form of a
predictor or its performance and therefore should be sub-
ject to verification when possible. Although it will not al-
ways be feasible to determine whether unusual-looking
data are erroneous, at the least the impact of any suspect
data on the model or its performance should be assessed.
12. Assess the developmental data sets for technical
artifacts (for example, effects of assay batch,
specimen handling, assay instrument or platform,
reagent, or operator), focusing particular attention
on whether any artifacts could potentially influence
the observed association between the omics profiles
and clinical outcomes.
Some features of omics profiles can arise from artifacts
introduced due to variations in specimen handling, assay
reagents, or instrumentation [36]. It is important to
check the omics data for evidence of these artifacts.
Methods of specimen handling or processing can change
over time or differ across clinical sites. Over time, la-
boratory instruments can drift, reagent lots can change,
and assay results can exhibit distinctive ‘batch effects’
due to changes in technique, environmental conditions,
or operators. Technology platforms (instrumentation,
software, and reagents) can become obsolete, requiring
replacement with new versions. A laboratory informa-
tion management system can be useful for tracking some
of these factors to allow for detection of possible prob-
lems and troubleshooting. Although attempts can be
made to correct for these artifacts through data adjust-
ment and/or use of replicated assays of analytical stan-
dards or calibrators, such adjustments often do not
completely remove them. The residual effects of these
artifacts introduce ‘noise’ into the data and may degrade
the performance of the omics predictor.
The best line of defense against technical artifacts in
the development stage of an omics predictor is quality
monitoring and good experimental design to avoid
confounding technical factors with important biological
effects or clinical outcomes [37]. For example, if speci-
mens from patient responders and non-responders were
assayed in separate batches, an omics predictor devel-
oped from those data might predict only assay batch,
not clinical outcome. This can be avoided by randomly
assigning specimens to assay batches. Other forms of
confounding can be more subtle. If patients accrued at
one clinical site tend to have worse prognoses than those
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process specimens differently in ways that affect the
omics profile, an omics predictor developed from such
data could end up predicting the specimen processing
method and have little true value for predicting clinical
outcome. Whenever possible, SOPs for specimen hand-
ling should be put in place across all clinical sites to
minimize these nuisance effects and avoid confounding
specimen handling with patient prognostic characteris-
tics that vary by clinical site. If it is not possible to
standardize procedures, or if existing collections of spec-
imens are being used (potentially accrued from multiple
clinical sites), it is important to demonstrate, perhaps
through multivariable statistical analyses, that the omics
predictor has the ability to predict outcome within each
clinical site and after adjustment for other standard clin-
ical or pathological variables.
Artifacts and confounding factors are frequently encoun-
tered in omics studies because it is often necessary to pool
across multiple clinical sites or multiple data sets to amass
a sufficiently large set of cases with omics data and clinical
and pathologic data with which to build or preliminarily
validate an omics predictor. Investigators who first collect
specimens and perform omics assays on those specimens
should make concerted attempts to record information
about specimen handling and ancillary assay variables such
as assay batch identifiers so that statistical analyses can be
performed to examine their influence on the omics profiles.
Unfortunately, this information is unavailable for many
retrospective data sets. However, it can sometimes be par-
tially recovered if primary omics data files produced by soft-
ware systems packaged with the assay platforms are
available. Depending on the omics assay platform, some of
this information may be embedded in the primary data files.
For example, the header lines in Affymetrix GeneChip CEL
files contain the date and often information about the la-
boratory or operator. The potential for these unknown
nuisance factors to affect the performance of an omics pre-
dictor underscores the need for external validation of omics
predictors before they are used to guide patient care.
13. Evaluate the appropriateness of the statistical
methods used to build the predictor model and to
assess its performance.
The high dimensionality of omics data and the com-
plexity of many algorithms used to develop omics pre-
dictors present many potential pitfalls if proper
statistical modeling and evaluation approaches are not
used. Various statistical methods and machine learning
algorithms are available to develop models, and each has
its strengths and weaknesses [38,39]. There is no uni-
formly best algorithm for developing a predictor model
[40]. One of the earliest studies to compare severalmethods for development of predictors from gene expres-
sion microarray data showed that simple linear diagonal
discriminant analysis and nearest-neighbor methods
performed as well or better than those developed with a
variety of more complex approaches on multiple data sets
[41]. A subsequent study conducted by the MicroArray
Quality Control Consortium [42] compared predictors de-
veloped by 36 independent teams analyzing six microarray
data sets to develop predictors for 13 cancer and toxicology
endpoints. That study concluded that the performance of
the predictors that were developed ‘depended largely on the
endpoint and team proficiency and that different ap-
proaches generated models of similar performance.’ More
complex modeling approaches, especially those involving
regularization (approaches to constrain complexity of
models) and optimized feature selection [43], theoretically
have the potential to produce better-performing predictors.
However, they are sophisticated tools that need to be ap-
plied by skilled hands. In situations where the number of
omics variables far exceeds the number of independent
subjects or specimens, current evidence from comparative
studies has not convincingly demonstrated the advantage of
highly complex modeling approaches.
A pervasive problem in the omics literature is that algo-
rithms to develop predictors are often applied naively, and
flawed approaches are used to assess the predictor’s per-
formance [40,44,45]. The more complex the algorithm, the
greater the chance that it will be misunderstood or applied
incorrectly in inexperienced hands. The two most common
pitfalls in developing predictors and assessing their per-
formance are model overfitting and failure to maintain
strict separation between the data used to build the pre-
dictor model and the data used to assess the predictor per-
formance. These two pitfalls occur in a large number of
published papers claiming to have developed omics predic-
tors with good performance [44,45]. The result is failure of
many omics predictors when they are tested on a truly in-
dependent data set [46,47].
Overfitting occurs when a statistical model describes
random error or noise instead of the underlying relation-
ship. Modeling strategies that allow for extremely com-
plicated relationships between one or more independent
variables and the dependent (outcome) variable and
models that are built from very large numbers of vari-
ables are particularly prone to overfitting because they
can exaggerate minor fluctuations in the data [40]. For
omics data, the number of variables that are available to
build a predictor typically greatly exceeds the number of
independent subjects for whom omics profiling data
have been obtained; therefore, the potential to overfit
models to high-dimensional omics data can be enor-
mous. For studies in which an omics predictor is devel-
oped for a time-to-event endpoint such as survival, the
number of observed events (for example, deaths) is a
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For diagnostic studies aiming to build a predictor for
disease state or class (for example, cancer or no can-
cer), the number of patients in the least prevalent class
most strongly affects the ability to develop a reliable
diagnostic model. Modeling approaches that include
regularization to constrain the complexity of the model
and limit the influence of individual variables or obser-
vations are particularly helpful in reducing the potential
for overfitting. When selecting among candidate
models, it is important to use appropriate procedures
to assess model performance to guard against incor-
rectly selecting an overfitted model. Overfitted models
will generally have poor predictive performance on new
data sets.
Validation of model performance on a completely
independent external data set is optimal, but there can
be ambiguity in the required degree of independence.
For the strongest independent external validation, the
specimens should be collected under the intended
conditions at a different site, and the assays should be
conducted according to the final SOP in a different
laboratory and by different laboratory personnel. If
sufficient numbers of patients or specimen sets are
available, a series of validations might be performed in
which an additional factor is varied in each successive
validation attempt to systematically establish robustness
of the omics predictor to these conditions. It is im-
portant to clearly describe the conditions under which
each validation is attempted so that the strength of
each validation can be evaluated in the proper context.
It is not always possible to obtain external data collected
under the exact target clinical setting and meeting all of
the quality standards for the most rigorous type of valid-
ation. In some cases, there might be an external data set,
but the specimens or assay protocols might not exactly
match those intended for the omics test; in other instances,
the clinical setting might be outdated, for example, because
standard treatment practices have changed. In these cir-
cumstances, one must rely on use of model development
techniques designed to avoid overfitting, and one can only
make assessments of performance internal to the data set
used to build the model.
Performance assessments based on re-use of data used in
model building are informative only when appropriate in-
ternal validation strategies are used. Despite standardization
of assays and attempts to avoid model overfitting, a pre-
dictor model will nearly always fit better to the data used to
develop it than it does to completely independent data. For
models built from high-dimensional omics data, simply
‘plugging in’ to a predictor exactly the same data that
were used to build it in order to estimate the predictor’s
performance — a so-called resubstitution estimate — results
in a highly optimistically biased estimate of performance[40,45]. Resubstitution estimates of performance for pre-
dictors built from high-dimensional omics data are
uninterpretable and should not be reported. Unfortu-
nately, resubstitution estimates of model performance
can still be found in some published articles. Appropri-
ate alternatives to the naïve resubstitution method are
available and should be used for internal validation.
The guiding principle for how to avoid optimistically
biased estimates of predictor performance is to never esti-
mate a predictor’s performance by using data that were
used to derive the prediction model. The easiest way to
ensure separation of model building and assessment is to
have completely independent training and validation data
sets so that an external validation can be performed. For
the most rigorous external validation:
 The predictor to be tested must be completely
locked down and there must be a pre-specified
performance metric. The lockdown includes all
steps in the data pre-processing and prediction
algorithm.
 The independent validation data should be
generated from specimens collected at a different
time, or in a different place, and according to the
pre-specified collection protocol.
 Assays for the validation specimen set should be run
at a different time or in a different laboratory but
according to the identical assay protocol as was used
for the training set.
 The individuals developing the predictor must
remain completely blinded to the validation data.
 The validation data should not be changed based on
the performance of the predictor.
 The predictor should not be adjusted after its
performance has been observed on any part of the
validation data. Otherwise, the validation is
compromised and a new validation may be required.
Internal validation can be used when no external valid-
ation set is available and is also helpful to use during the
model building stage to generate preliminary estimates
of model performance to monitor and guard against
overfitting. Either the original data set can be split into
‘training’ and ‘testing’ subsets [48] or a variety of data
resampling techniques can be used to iteratively build
the predictor model on a portion of the data and test it
on the remaining portion.
Split-sample validation, in which a single data set is
split into two parts, has the advantage of being compu-
tationally simple. It also provides the flexibility needed
to make subjective decisions in the model building
process on the training portion of the data. As a further
check on model performance in split-sample validation,
one can interchange the training and testing subsets to
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have similar performance on the other subset [42].
Sometimes what is viewed as a single data set may actu-
ally be an amalgamation of several smaller sets. Different
portions of the data might represent omics data that
were generated in different laboratories or from speci-
mens collected at different clinical sites. Even if all la-
boratories and clinical sites followed a common protocol
for specimen collection and omics assays, subtle differ-
ences can arise. In this situation, the most challenging
type of split-sample validation, and most representative
of ‘real world’, is to partition the data into training and
testing sets to minimize the overlap in the laboratories
or clinical sites represented in the two sets. A disadvan-
tage of split-sample validation is its inefficiency. This is
because only a fraction of the data is ever used to build
the predictor model. Split-sample validation applied to
small or moderate size data sets tends to yield biased re-
sults because it underestimates the performance of a
model that could be built using the entire data set.
Resampling methods have an advantage over split-
sample validation in that they use the full data set but it-
eratively select which portion of the data serves as a
training set, so that at the end of the iterations, each
case has been in at least one training subset and in at
least one validation subset. Examples of resampling
methods include various forms of cross-validation (for
example, leave-one-out, k-fold where typically k = 5 or
10) and bootstrapping. The best choice of resampling
method for a particular problem depends on the size of
the data set and the desired trade-off between bias in
the performance estimate and variance of the perform-
ance estimate [49].
Internal validation has two major limitations. First, if
the cases selected for study are not representative of the
intended-use population or there are technical artifacts
affecting the entire data set, any subsets of the data will
inherit those same problems. This is especially of con-
cern when the bias is from technical artifacts that con-
found the association between the omics profiles and
the clinical endpoint of interest (for example, specimens
from patients with favorable clinical outcomes run in a
different assay batch than those from patients with un-
favorable clinical outcomes). This can lead to biased esti-
mates of test performance that cannot be detected
unless the test is evaluated on a completely independent
data set not subject to these same problems. Second, it-
erative resampling methods are applicable only if the
process used to build the predictor model is entirely al-
gorithmic and requires no subjective judgment. Subject-
ive judgment can potentially and subtly enter into
several aspects of building predictor models. These as-
pects may include decisions about constraints on the
number of variables in the model, constraints on theweight given to any single variable, how to handle un-
usual measurements, how to summarize redundant vari-
ables, and where to set cutpoints on risk scores for
clinical decision making. Although many of these as-
pects can be decided in a fully algorithmic fashion, many
investigators are reluctant to rely on completely auto-
mated model building methods.
The principle of separation of training and validation
sets can be violated in several more subtle ways. Some-
times investigators use a split-sample approach and de-
velop a predictor model using only a portion of the data,
but then present the model performance estimates on
the combined training and validation sets rather than on
the validation set only, as would be appropriate. This
still leads to an optimistic bias in the performance as-
sessment because the resulting performance estimate is
a hybrid of an optimistically biased resubstitution esti-
mate on the training data and an independent estimate
on the validation data [50]. Another common error
made when applying iterative resampling validation ap-
proaches is to perform an initial screen for omics vari-
ables using the entire data set to identify those variables
that are univariately most informative for predicting the
clinical outcome of interest, and then to perform itera-
tive resampling to fit the predictor model using only that
subset of selected variables. The leak of information
resulting from that initial screening on the full data set
to reduce the number of variables can be substantial and
can lead to optimistic bias in performance estimates
nearly as large as for resubstitution estimates [40,51].
Other practices that can introduce bias into the
reported performance of a predictor model include se-
lective inclusion or exclusion of certain cases in either
the training or the validation sets to obtain improved es-
timates of predictor performance, testing performance in
multiple patient subgroups within the full cohort, and
trying multiple model building strategies on the training
set, but then reporting only the one that yields the best
performance estimate on the validation set. All of these
practices are examples of multiple testing, and they can
lead to spurious findings and optimistically biased esti-
mates of reported predictor performance.
Regrettably, numerous papers published in reputable
journals reporting to have developed omics predictors
with good performance have used flawed methods of
evaluating predictor performance such as those just
discussed. Thus, publication in a peer-reviewed journal
should not be taken as assurance that the performance
of an omics predictor has been confirmed. Published ar-
ticles should be critically reviewed for soundness of the
methods used. If sufficient information about the
methods is not provided in the published article, it may
be necessary for this information to be obtained directly
from the predictor developers, along with any primary
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ently reproduce the predictor development and valid-
ation results before the omics predictor is used to direct
therapy in a clinical trial.
14. Establish that the predictor algorithm, including all
data pre-processing steps, cutpoints applied to
continuous variables (if any), and methods for
assigning confidence measures for predictions, are
completely locked down (that is, fully specified)
and identical to prior versions for which
performance claims were made.
A multitude of steps occur from the point at which
primary omics data are generated from a specimen until
a final result is produced from the omics predictor.
These include data pre-processing steps such as overall
data quality assessments, exclusion of unreliable mea-
surements, data normalization, calculation of intermedi-
ate summary statistics (for example, calculation of gene-
level summary expression levels from probe intensity
values in microarray data), calculation of a score (pos-
sibly subjected to a cutpoint for clinical decision mak-
ing), or prediction of an outcome. A standardized
format for reporting the test result should be developed
to ensure proper clinical interpretation. Elements of the
report might include a continuous score (for example,
probability of disease recurrence) or discrete classification
(for example, disease subtype) or both, perhaps accompan-
ied by some measure of confidence or statistical uncer-
tainty interval for the result (for example, strong positive,
equivocal, ‘uncertainty in risk score is ±10%’) and a
recommended clinical action (for example, consider adju-
vant chemotherapy, contraindication for a drug class).
Before an omics predictor is used in a clinical setting
where it will influence patient care, all aspects of the
data processing and prediction calculation and reporting
should be recorded in a detailed, dated SOP document
and should remain unchanged from their form when the
predictor forming the basis for the clinical test was
locked down for the final validation. Changes to any of
these steps, including adjustments to cutpoints applied
to continuous risk scores, can alter the performance
characteristics of a predictor. Such changes may necessi-
tate a new validation of the predictor before it is used to
direct patient care unless other results, for example,
from an assay bridging study, can provide convincing
evidence that the performance of the predictor has not
been adversely affected by the changes. Several reprodu-
cible research software and data management systems
that can be helpful to document the process of building
and validating predictors are now available (for example,
Accessible Reproducible Research [52], GenePattern [53],
Sweave [54], knitr [55], markdown with Rstudio [56], git[57]). To achieve complete transparency in the omics test
development process, raw data should be made available
for review, and the data sources should be identified. Eval-
uations performed to assess data quality and to check for
technical artifacts should be reported. The computational
environment (languages, software versions, libraries, hard-
ware, and cloudware) should be identified, and program-
matic scripts used in data pre-processing (for example,
normalization) and model development and testing should
also be available for review. Public access to all of the
above is desirable, but at minimum, these items must be
available for review by the sponsors and relevant oversight
bodies for the proposed trials in which the omics predictor
is to be used.
15. Document sources of variation that affect the
reproducibility of the final predictions, and provide
an estimate of the overall variability along with
verification that the prediction algorithm can be
applied to one case at a time.
The association between an omics test result and the
clinical outcome the test is intended to predict will be at-
tenuated if the testing process lacks reproducibility. Test
results obtained for a given individual can vary for numer-
ous reasons, including biological heterogeneity of the spe-
cimen (for example, distinct clonal subpopulations of cells
or necrotic regions in a tumor), variation in specimen
handling, technical variation in the assay, and numerical
variation in the prediction algorithm. Some of these
sources of variation can be controlled and others cannot.
Biological heterogeneity within a specimen cannot be con-
trolled, but it must be understood. If there is substantial
biological heterogeneity and it cannot be determined that
one portion or region of the specimen provides the omics
information of most relevance to the clinical outcome (for
example, the leading edge of the tumor, the area of the
tumor with highest grade, or the stem cell compartment),
then it is unlikely that the omics test will produce clinic-
ally reproducible and informative results. Variation due to
specimen handling and assay technical variation is best
controlled through careful specification of SOPs and
quality monitoring. Numerical variation in the predic-
tion algorithm can be controlled through choice of the
algorithm or algorithm settings. Multiple reproducibil-
ity assessments may be required to fully understand the
relative contributions of all of these sources of variation
to the overall variation in the predictions that could be
obtained for a given individual.
Reproducibility assessments should be reported in suf-
ficient detail to allow others to understand the sources
of variation that are being evaluated. For example, two
separate portions of a tumor that are independently
subjected to the analyte extraction process (for example,
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cedure (for example, gene expression microarray ana-
lysis), and prediction algorithm would be expected to
exhibit more variability than replicate assays of a single
sample of extracted analyte that is split and run through
the omics assay process and prediction algorithm. Stud-
ies should be conducted to evaluate the robustness of
omics test results to variations in specimen collection,
processing, and storage if tight controls on these factors
are not specified as part of the SOPs for the testing
process. Specimens used in reproducibility studies
should be comparable to the clinical samples for which
use of the omics test is being proposed. Because more
highly reproducible results are likely to be obtained on
cell lines or artificially derived specimens that have been
carefully prepared in a laboratory setting than on actual
clinical samples that were collected under less predict-
able conditions, variability assessments made on cell
lines or other derived specimens are likely to substan-
tially underestimate the variability that could be experi-
enced in clinical practice.
Variation in predictions due to the numerical algo-
rithm that mathematically evaluates the model is the
most straightforward to assess. This variation can be
assessed independently of the biological and assay tech-
nical variation, but it will still contribute to the overall
variation in the predictions for any given individual. This
numerical variation arises only for prediction models
that cannot be evaluated as a simple formula and require
evaluation by an iterative or stochastic computerized al-
gorithm. A stable computer algorithm should produce
highly similar results when exactly the same primary
omics data are used on independent occasions as the
model input. Often computerized algorithms are needed
because evaluation of the prediction model involves
complex mathematical equations that can be solved only
by the use of iterative numerical approximations. For ex-
ample, Markov Chain Monte Carlo methods are iterative
mathematical algorithms often used in Bayesian statis-
tical modeling approaches [58]. Other prediction model-
ing approaches require a computer algorithm because
they involve combining many models or decision algo-
rithms where each component model or algorithm is
built using only a randomly selected subset of the pa-
tient data (for example, random forests [59,60]) or using
only a small subset of randomly chosen variables among
a much larger number of variables available (for ex-
ample, shotgun stochastic search [61]). In these situa-
tions, any variability associated with the iterative
calculation or random-component model selection is in-
corporated into the variability of the final predictions.
Depending on the particular algorithm used and the data
set to which the algorithm is applied, it is possible that
the randomness introduced by the computerizedalgorithm could be substantial. This variability becomes
part of the variability in the test result and must be
assessed along with the assay analytical performance (see
Criterion 8). Sometimes such instability can be
addressed through measures such as locking down ran-
dom number seeds used by iterative numerical algo-
rithms or by saving information about the exact
component models that are combined into a final model.
If the numerical variability in the final results cannot be
adequately controlled, then these complex models will
not be suitable for making clinical predictions where it is
expected that the same set of observed omics variables
should lead to a consistent final test result.
Many studies in which omics predictors have been de-
veloped have used data pre-processing methods that in-
duce interdependencies of pre-processed data or
predictions made on a collection of specimens. One cir-
cumstance in which this occurs is when the pre-
processing or prediction algorithm that is applied to an
individual specimen depends on the other specimens
that happen to be processed with it. A simple example
of when such a dependency could occur is when each
measured variable is centered by subtracting that vari-
able’s mean value calculated across a collection of speci-
mens. A more complex example is the widely used
Robust Multi-array Average method for calculating
gene-level summaries from probe sets in the Affymetrix
GeneChip system [62,63]. The Robust Multi-array Average
method incorporates data from a collection of microarrays
to fit a model that includes terms to estimate probe-
specific sensitivities, and it is used to produce the gene-
level summaries for each probe set on an Affymetrix
GeneChip. For implementation in a clinical trial in which
individual patients will be accrued to the trial over time,
methods that require group processing of omics profiles
must be modified to allow for processing one omics profile
at a time. Some investigators have addressed this issue by
using a fixed reference set of omics profiles to which each
new omics profile is added and then removed for purposes
of pre-processing data [64-66].
Some early methods of identifying tumor subtypes, such
as intrinsic breast cancer subtypes [67,68] or subtypes of
diffuse large B-cell lymphomas [69], used clustering
methods. These clusters were found to have prognostic sig-
nificance in addition to biological significance, but in order
to be applicable to the classification of single specimens
from individual patients, prediction algorithms had to be
developed. Clustering algorithms used to identify subtypes
may produce results that are sensitive to data pre-
processing methods such as variable centering and may be
dependent on the characteristics of the collection of speci-
mens that are processed together [70]. Therefore, a pre-
dictor model has to be developed to reliably identify the
subtypes without having to use clustering methods or other
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mens in order to make a prediction for a single case. For
example, a risk prediction model was developed into a clin-
ical test that could make a diagnosis of an intrinsic breast
cancer subtype for a single patient tumor sample [71]. The
basic principle is that one should be able to perform all the
steps of the omics assay and prediction algorithm to pro-
duce a result for a given specimen without regard to other
specimens that are being evaluated at the same time.
16. Summarize the expected distribution of predictions
in the patient population to which the predictor
will be applied, including the distribution of any
confidence metrics associated with the predictions.
Many omics predictors are developed on existing data
sets or on retrospective collections of specimens. The cases
included in those studies do not necessarily comprise a rep-
resentative sample of the clinical population for which the
omics test is intended, or from any well-defined population.
Sometimes cases are intentionally selected to overrepresent
extremes of clinical outcome (for example, very short- or
very long-term survivors). In other circumstances, the col-
lection of cases studied are non-representative due to other
practical constraints, such as ability to obtain consent, vital
status of the patient, or amount of available specimen. In
addition, some prediction algorithms produce a confidence
metric associated with each prediction, which might relate,
for example, to the proximity of a prediction risk score to a
previously defined cutpoint for clinical classification. If the
patients whose specimens were used in the developmental
studies were not representative of the intended-use popula-
tion, the distribution of the predictions and their associated
confidence metrics in the developmental studies might not
be representative of the distribution expected when the test
is applied in clinical practice. If the predictions in the
intended-use population are highly skewed toward
predicting one clinical outcome over another, or if many
predictions have low associated confidence, the predictor
may not have a sufficiently large clinical impact to be useful.
Therefore, assessment of these distributions should play a
role in the decision about whether to pursue the clinical de-
velopment of an omics predictor.
17. Review any studies reporting evaluations of the
predictor’s performance to determine their
relevance for the setting in which the predictor is
being proposed for clinical use.
Many studies report to have performed validations of
omics predictors, but the term ‘validation’ is used in
many different ways. A variety of questions should be
asked to assess the strength and relevance of any study
that claims to have validated an omics predictor.Sometimes a technical validation has been performed to
show that an alternative assay methodology produces
measurements that have significant correlation with the
originally measured omics variables. Although technical
validations provide some assurance that the study results
are not wholly artifacts of the assay process, they do not
provide any clinically relevant validation. Other types of
validations in preclinical systems, for example, drug sen-
sitivity experiments in cell lines, may support biological
plausibility, but they do not provide clinical validation.
For a study to provide a clinical validation, there must
be a predefined and clinically meaningful performance
metric for the predictor, and the clinical setting (for ex-
ample, disease type and stage, specimen format) must be
similar to the intended-use setting.
There are well-established criteria for evaluating the
performance of models used to predict risk [72-74], and
guidelines have been developed for informative
reporting of studies on the prediction of genetic risk
[75] and on prognostic [76,77] and diagnostic [78,79]
markers. These criteria and guidelines are applicable to
a wide variety of omics predictors. The specific choice
of performance metric (for example, sensitivity and spe-
cificity, positive and negative predictive value, C-index,
area under the receiver operating characteristic curve)
[72-74] and the benchmark performance level that must
be attained will be dependent on the intended clinical
use. An omics test intended for screening a large healthy
population for disease (for example, a serum proteomic
screening test for ovarian cancer) must have very high
specificity and positive predictive value, and its predict-
ive value must be calculated by using a disease preva-
lence that is appropriate for the intended screening
population [80]. A test intended to predict the risk of
disease recurrence to guide decisions about additional
therapy (for example, a recurrence risk score to identify
patients with early-stage breast cancer who do or do not
need adjuvant chemotherapy) should have high sensitiv-
ity to identify patients in whom disease will recur. Dem-
onstration that a predictor’s output is statistically
significantly associated with the clinical endpoint it aims
to predict is not sufficient evidence of acceptable per-
formance for clinical use [81].
18. Evaluate whether clinical validations of the
predictor were analytically and statistically
rigorous and unequivocally blinded.
Unequivocal evidence of rigorous validation is required
whenever a predictor is proposed for use in a clinical trial
where it will influence patient care. Ideally, this should be a
blinded external validation on a completely independent
specimen set. Requirements for a rigorous blinded external
validation include signed and dated documentation that the
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the release of any validation data. This documentation must
include an SOP for all aspects of the omics assay, including
data processing steps and the prediction algorithm. A
mechanism for blinding of clinical outcome data should
have been in place, for example, under control of a third-
party ‘honest broker’ or an independent statistics and
data center that maintains data in a secure system that
complies with US Food and Drug Administration
(FDA) guidelines for the maintenance of clinical data
in computerized systems [82]. If an external validation
is not possible because, for example, no appropriate
independent specimen set is available, then existing re-
sults from internal validations must be carefully evalu-
ated to determine whether the internal validations
were rigorous enough to provide reasonable confi-
dence in the predictor’s performance. Findings of any
validation attempts should be reported regardless of
whether the results were favorable or unfavorable.
19. Search public sources, including literature and
citation databases, journal correspondence, and
retraction notices, to determine whether any
questions have been raised about the data or
methods used to develop the predictor or assess
its performance, and ensure that all questions have
been adequately addressed.
Omics research has been at the forefront of efforts to
promote the public availability of data, and there has
been unprecedented sharing of computational algo-
rithms and computer code. Without this sharing of data
and algorithms, the sheer volume of data and the com-
plexity of many analyses conducted with omics data
would have made it virtually impossible to reproduce
many omics study results. On occasion, questions arise
about data or analytic approaches when others try to re-
produce results using publicly available data, methods,
or computer code. Whenever an omics predictor is to be
used in a trial or other clinical setting where it will influ-
ence patient care, there must be transparency so that
any concerns about accuracy of data or appropriateness
of methods can be promptly and fully addressed before
resources are expended to pursue further development
of the predictor, and certainly before the predictor is
used clinically.
Clinical trial design
20. Provide a clear statement of the target patient
population and intended clinical use of the
predictor and ensure that the expected clinical
benefit is sufficiently large to support its clinical
utility.Many published omics studies report statistically sig-
nificant associations between omics predictor results
and clinical endpoints. Although the presence of such an
association may establish the clinical validity of the test,
statistical significance (for example, P <0.05) does not al-
ways translate into a clinically meaningful association or
provide clinically useful information. Unless the omics
predictor provides new information that is readily inter-
pretable and useful to the physician and patient in mak-
ing treatment decisions, the investment of resources in
developing a clinical test may be wasted. To establish
clinical utility, as opposed to clinical validity, there must
be evidence suggesting that use of the test is likely to
lead to a clinically meaningful benefit to the patient be-
yond that provided by current standards of care [83,84].
Design of a clinical trial for definitive evaluation of an
omics test must begin with a clear statement of the target
population and the intended clinical use. Information
about the anticipated distribution of test results in the
population and the magnitude of the expected effect or
benefit from use of the test should be gathered from pre-
clinical or retrospective studies. On the basis of that infor-
mation, it should be determined whether it will be feasible
to design a trial or clinical study of sufficient size to dem-
onstrate clinical utility. Ideally, the size of the expected
benefit from use of the omics test will have been estimated
from multivariable analyses as being beyond that provided
by knowledge of standard clinical or pathologic factors.
21. Determine whether the clinical utility of the omics
test can be evaluated by using stored specimens
from a completed clinical trial (that is, a
prospective–retrospective study).
In some instances, a candidate prognostic or predictive
omics test for an existing therapy can be evaluated effi-
ciently by using a prospective-retrospective design, in
which the omics test is applied to archived specimens
from a completed trial and the results are compared with
outcome data that have already been collected [85]. The
retrospective aspect of this design requires that the assay
can in fact be performed reliably on stored specimens.
The ‘prospective’ aspect of the design refers to the care
taken at the outset of the trial to ensure the following:
 The patients in the trial are representative of the
target patient population expected to benefit from
the omics test.
 There is a pre-specified statistical analysis plan.
 Sufficient specimens are available from cases that
are representative of the trial cohort and intended-
use population to fulfill the sample size
requirements of the pre-specified statistical plan,
and those specimens have been collected and
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intended-use setting.
In general, two such prospective-retrospective stud-
ies producing similar results will be required to have
confidence that the clinical utility of the test has been
established.
22. If a new prospective clinical trial will be required,
evaluate which aspects of the proposed predictor
have undergone sufficiently rigorous validation to
allow treatment decisions to be influenced by
predictor results; where treatment assignments are
randomized, provide justification for equipoise.
A variety of designs have been proposed for phase III
clinical trials incorporating biomarkers [86-88]. There
are three basic phase III design options that are fre-
quently considered for assessing the ability of a bio-
marker to identify a subgroup of patients who will
benefit from a new therapy. These are the enrichment
design, the stratified design, and the strategy design. In
the enrichment design, only patients who are positive
for the biomarker are randomized to the standard or
new therapy. This approach can answer the question of
whether biomarker-positive patients benefit from the
new therapy, but it cannot be used to empirically assess
whether biomarker-negative patients might benefit as
well. The stratified design randomizes all patients but
conducts the randomization separately with each of the
biomarker-positive and -negative groups to ensure bal-
ance of the treatment arms within each group. This ap-
proach provides maximum information about the ability
of the biomarker to identify patients who will benefit
from the new therapy. A stratified design does not allow
the biomarker to influence what treatment a patient re-
ceives. This can be an advantage in a situation where
there is some uncertainty about the strength of a bio-
marker’s performance because there were limited speci-
mens available on which to perform preliminary
validations during the biomarker development process.
The strategy design randomizes patients between no use
of the biomarker (all patients receive standard therapy
on that arm) and a biomarker-based strategy where
biomarker-negative patients are directed to standard
therapy and biomarker-positive patients are directed to
the new therapy. A strategy design in the context of a
single biomarker is particularly inefficient because pa-
tients who are negative for the biomarker will receive
standard therapy regardless of whether they are random-
ized to use the biomarker. Due to this inefficiency, this
strategy design is generally not recommended in a sim-
ple single-biomarker setting. Each of these designs has
its advantages and disadvantages; the optimal choicedepends on feasibility and what properties have already
been established for the biomarker.
Many of the same principles discussed for phase III
trials also apply to phase II trials. Some ways in which
phase II designs may differ from phase III designs in-
clude alternative or ‘earlier’ endpoints (for example, dis-
ease progression or tumor response) and the possibility
of non-randomized (for example, single-arm) trials [89].
Just as for drug trials, phase II designs incorporating bio-
markers are generally not definitive and serve mostly as
a screen to determine whether there is sufficient promise
to proceed to a phase III trial. A recently proposed ran-
domized biomarker-based phase II trial design has as its
primary aim the generation of sufficient data to inform
the decision about the best design for a subsequent
phase III trial [90].
Lastly, the same basic design considerations for trials
incorporating single biomarkers apply to omics tests,
even though it can be more difficult to properly evaluate
the body of evidence for an omics test to determine its
readiness for use in a clinical trial. The difficulties lie in
the complexity of some predictors and the generally in-
complete reporting of methods and results for such
studies. By considering the criteria presented here, it is
hoped that the body of evidence will be more systemat-
ically and thoroughly reviewed before omics tests are ap-
plied in clinical trials where they will be used to guide
treatment decisions.
To prepare for a prospective phase II or phase III trial
that will use an omics test, a thorough review should be
conducted of all retrospective validation studies of the test
to assess the evidence for both its prognostic value and its
predictive ability. This review should be undertaken before
it is proposed that a prospective clinical trial be conducted
to definitively evaluate the clinical benefit of the test (clinical
utility). ‘Prognostic’ refers to the ability of a test to predict
clinical outcome in the absence of therapy (that is, natural
history) or in the presence of a standard therapy that all pa-
tients are likely to receive. ‘Predictive’ (also called treatment
effect modifier, treatment selection, or treatment guiding)
refers to the ability of a test to predict benefit or lack of
benefit (potentially even harm) from a particular therapy
relative to other available therapies. Most developmental
studies provide evidence of only some prognostic value
of a predictor but do not provide convincing evidence of
its predictive value, which is best assessed in the context
of a randomized trial. Even a prospective-retrospective
study might not be an option to establish predictive util-
ity if there are no specimens available from a trial with
the relevant and well-controlled treatment randomization.
In some situations, when the prognostic value of a test
has been established as sufficiently robust in retrospect-
ive studies, the test can be used in a prospective clinical
trial to limit the group of patients who should be
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the TAILORx (Trial Assigning IndividuaLized Options for
Treatment; NCT00310180) trial in patients with node-
negative, hormone receptor-positive, HER2-negative breast
cancer [91,92]. That adjuvant trial tested more than 10,000
tumors for the 21-gene recurrence score, assigning patients
with low-risk scores to adjuvant endocrine treatment and
those with high-risk scores to standard-of-care adjuvant
chemotherapy or adjuvant chemotherapy treatment trials,
in addition to adjuvant endocrine treatment. Patients with
intermediate-risk scores were randomized to receive endo-
crine therapy with or without chemotherapy as adjuvant
treatment. It was thought to be firmly established that the
risk of recurrence for patients with a value of the 21-gene
recurrence score in the low-risk range was so small that
those patients had very little potential to benefit from the
addition of chemotherapy to hormonal therapy. This con-
clusion was supported by high-quality evidence from a
prospective-retrospective study conducted with banked
specimens from the tamoxifen arm of a large clinical trial
[93], and additional confirmation was provided in a subse-
quent case-control study [94]. Information about the benefit
of chemotherapy for patients with risk scores in the inter-
mediate range was considered to be inconclusive, and the
absolute risk of recurrence for those intermediate-risk
patients was still fairly favorable; thus it was believed that
there was sufficient equipoise about the benefit of chemo-
therapy in the intermediate-risk group to randomize those
patients.
Another frequently encountered situation is one in
which an omics test is developed to identify patients
who will benefit from a new therapy. Often there is little
information about the potential benefit of the new ther-
apy in patients who test ‘negative’ for the omics test, be-
cause the development studies have honed in quickly on
the test-positive cases. To provide the most rigorous as-
sessment of the ability of the omics test to predict benefit
of the new treatment, one should ideally also randomize
test-negative patients to receive or not receive the new
therapy. For randomization of test-negative patients to be
considered ethical, however, there must be careful examin-
ation for evidence of any potential risks, including not
only risks due to toxicities of the new therapy but also any
risk of receiving an ineffective new therapy in lieu of an
established effective therapy, if that is the randomization
being proposed. If a trial will randomize test-negative pa-
tients, there should be provisions for aggressive futility
monitoring so that the trial can be stopped early if sub-
stantial evidence emerges that these patients are not bene-
fitting from the new therapy.
23. Develop a clinical trial protocol that contains
clearly stated objectives and methods and an
analysis plan that includes justification of samplesize; lock down and fully document all aspects of
the omics test and establish analytical validation of
the predictor.
A clinical trial to evaluate the clinical utility of an omics
test should be conducted with just as much rigor as a clin-
ical trial to evaluate a new therapy. This includes develop-
ment of a formal protocol clearly detailing pre-specified
hypotheses, study methods, and a statistical analysis plan.
Like the formulation of a new drug, all aspects of the omics
test should be clearly specified, either in the main protocol
or as a supplement to the protocol. The information to be
documented includes details of the specimen requirements,
assay SOPs, data quality assessments, data pre-processing,
specification of the mathematical predictor model, and in-
terpretation and reporting of the output of the predictor
model for clinical decision making. The omics test must be
analytically validated in accordance with the relevant regula-
tory requirements (see ‘Ethical, legal, and regulatory issues’)
before it is used in a trial where it will influence patient care.
International working groups such as the International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use [95]
have issued several guidance documents outlining the prin-
ciples of good clinical practice and statistical principles for
clinical trials (Guidelines E6-R1, E8, E9, and E10); investiga-
tors are also expected to adhere to these principles when
conducting clinical trials involving the use of omics tests.
24. Establish a secure clinical database so that links
among clinical data, omics data, and predictor
results remain appropriately blinded, under the
control of the study statistician.
Good clinical practice requires that clinical data be
maintained in a secure clinical database with access con-
trols and quality assurance procedures in place to ensure
data integrity. The same good practices should be
followed for maintaining and managing the omics data
and predictor results. Blinding should be maintained
under the control of the study statistician and linkages
made between the clinical data and omics test results
only when needed for the protocol-specified interim
monitoring and for the final definitive analysis. Investi-
gators are expected to adhere to the principles outlined
in the FDA Guidance for Industry: Computerized Sys-
tems Used in Clinical Investigations [82].
25. Include in the protocol the names of the primary
individuals who are responsible for each aspect of
the study.
Successful omics-based clinical research requires an
interdisciplinary team of experts, generally including
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bioinformaticians, database developers, computational
scientists, data managers, and regulatory experts. A
standard therapy trial team may not sufficiently cover all
of these areas of expertise. It is important that the need
for these varied types of expertise is fully recognized and
that involvement of the essential individuals is docu-
mented by naming the specific responsible individuals in
the protocol document.
Ethical, legal, and regulatory issues
26. Establish communication with the individuals,
offices, and agencies that will oversee the ethical,
legal, and regulatory issues that are relevant to the
conduct of the trial.
Legal, ethical, and regulatory issues must be consid-
ered for an omics test to proceed from the research la-
boratory to the clinic. In particular, the developer needs
to consider federal, state, and local laws regarding hu-
man participant protection issues [96]; the environment
and procedures necessary for performing in vitro diag-
nostic tests; and intellectual property considerations for
the test, specimens omics assay platform, and computer
software. Careful attention must be paid to the potential
for real or perceived conflicts of interest on the part of
investigators, institutions, and sponsors. Appropriate
safeguards and oversight must be in place; potential risks
and disclosures of conflicts of interest must be clearly
acknowledged (see Criterion 27). Navigation of the eth-
ical, legal, and regulatory aspects of using an omics pre-
dictor in a clinical trial is best approached with a team
[83]. Roles of relevant individuals, offices, and institu-
tions should be clearly defined at the outset. Within the
primary institution this will probably include a Principal
Investigator, a Trial Sponsor, an Institutional Review
Board, and a Technology Transfer Office (TTO). Exter-
nal contacts might include institutes within the National
Institutes of Health or other funding agency, a Coopera-
tive Clinical Trials Group, commercial partners, and the
therapeutic product and medical device divisions of the
FDA (Center for Biologics Evaluation and Research,
Center for Drug Evaluation and Research, Center for De-
vices and Radiological Health). All members of the team
have an interest and responsibility to ensure that ethical,
legal, and regulatory requirements for using the omics
predictor in the context of a clinical trial are compre-
hensively addressed.
27. Ensure that the informed consent documents to be
signed by study participants accurately describe the
risks and potential benefits associated with use of the
omics test and include provisions for banking ofspecimens, particularly to allow for ‘bridging studies’
to validate new or improved assays.
When an omics test is to be used in a clinical trial where
it will guide patient care or require that a patient undergo
a procedure that is not part of standard care, appropriate
informed consent must be obtained. The consent forms
must accurately describe the risks and potential benefits
associated with use of the test (and state that the test itself
is investigational, if it has not received FDA approval or
clearance). All potential conflicts of interest on the part of
the study investigators or sponsoring institutions must
also be disclosed in the informed consent documents. The
participant must be informed of the degree of likelihood
that the test result will be wrong (and how frequently this
is expected to occur), potentially resulting in inaccurate
treatment assignment. The participant should understand
the likely consequences should an erroneous treatment as-
signment occur. Potential adverse events from the testing
process, for instance, from an invasive tissue biopsy, must
be clearly explained. Informed consent should also address
banking specimens to allow for ‘bridging studies’ that use
the specimens collected during the trial to subsequently
validate new or improved assays. The investigator is re-
sponsible for ensuring that the use of an omics predictor
in a clinical trial is reviewed by the responsible parties at
participating institutions (for example, Institutional Re-
view Board, protocol review committee), trial sponsors
(for example, National Cancer Institute, universities, com-
panies), and the FDA (for example, through Investigational
Device Exemption (IDE) and/or Investigational New Drug
applications; see Criterion 30).
28. Address any intellectual property issues regarding
the use of the specimens, biomarkers, assays, and
computer software used for calculation of the
predictor.
The investigator should address any intellectual prop-
erty issues for use of the specimens, biomarkers, assays,
and computer software used for calculation of the pre-
dictor. Intellectual property claims can apply to many
aspects of an omics test. For instance, the claims can at-
tach to the specimens used to develop the test, the ana-
lyte(s) being measured, the assays themselves or
components thereof, and/or the computer software used
for calculation of the test result. Before developing the
test, it is wise to investigate all potential sources of intel-
lectual property to determine whether any rights exist. It
is likewise advisable to anticipate any intellectual prop-
erty that may be generated in the development process
and to agree in advance how it will be designated. All
existing property rights and agreements concerning fu-
ture rights should be clearly documented and distributed
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tutional TTO should determine early in the course of
assay development whether there are patents on
intended biomarkers or the assays to measure them (or
components of the assays) that could restrict freedom to
operate or develop the test. If there are such patents, the
TTO and investigator should contact the patent holder
early and determine whether licensure or other accommo-
dations may be made to enable further development. For
example, the National Cancer Institute's Cancer Therapy
Evaluation Program (CTEP) has agreements with pharma-
ceutical companies concerning the use of specimens from
CTEP-sponsored trials in which the companies have cer-
tain rights to any inventions that derive from specimens
from patients who were treated with the company’s agent.
The TTO and investigator should inquire about these
rights when considering use of specimens from such trials.
More information is available at the CTEP website [97].
29. Ensure that the omics test is performed in a
Clinical Laboratory Improvement Amendments-
certified laboratory if the results will be used to
determine treatment or will be reported to the
patient or the patient’s physician at any time, even
after the trial has ended or the patient is no longer
participating in the study.
The assay developer is responsible for ensuring that the
omics test is performed in an appropriate environment
with adherence to good laboratory practice. If test results
will be reported to the patient or the patient’s physician at
any time, even after the patient comes off the study, the
assay must at least be performed in a CLIA-certified
laboratory [98]. CLIA was enacted by Congress in 1988,
and thus this requirement is federal law. CLIA is adminis-
tered by the Centers for Medicare and Medicaid Services.
There may also be applicable state laws imposing add-
itional requirements that must be followed for the per-
formance of in vitro diagnostic tests [99-103].
30. Ensure that appropriate regulatory approvals have
been obtained for investigational use of the omics
test. If a prospective trial is planned in which the
test will guide treatment, consider a pre-submission
consultation with the US Food and Drug
Administration.
Federal regulations for investigational and clinical use
of in vitro diagnostics also apply to omics tests. The in-
vestigator should contact the FDA early in the planning
stages of a trial that will use an omics test to ascertain
whether an IDE must be filed [104]. IDE regulations
[102] apply to any device, as defined by the FDA [103],
that poses significant risk. An IDE is designed to allowthe collection of safety and effectiveness data to support
further development toward marketing the device and
may be required before an omics predictor can be used
in a clinical trial. For predictive tests, an IDE for the pre-
dictor may be requested as part of the Investigational
New Drug application [100] for the companion drug. A
device review considers the omics assay as well as other
aspects of use of the test, including procedures required
to obtain the specimen, the mathematical predictor
model, and the format of the results report. It is advis-
able to obtain a Pre-Sub (formerly known as a pre-IDE)
consultation with the Office of In Vitro Diagnostic De-
vice Evaluation and Safety in the Center for Devices and
Radiologic Health of the FDA. A Pre-Sub is a free, non-
binding consultation with FDA personnel that can help
determine the regulatory mechanism, if any, that best
suits the development plan [103,104].
Regulatory classifications are determined by intended
use and potential risk. Pertinent risks associated with
use of a device could be related to specimen collection
procedure (for example, risk of a biopsy), performance
of the test, or effects of therapy indicated by results pro-
duced by the test, but also could be social or psycho-
logical, depending on the intended use of the test. The
FDA uses several classifications that may apply to an
omics predictor. An In Vitro Diagnostic Multivariate
Index Assay refers to any assay that uses multiple vari-
ables to yield a patient-specific result whose derivation is
not easily verifiable by the end user [101]. The FDA re-
cently introduced a Biomarker Qualification mechanism
[105] to streamline the scientific development of bio-
markers and their use in the drug development process.
The qualification of a biomarker is independent of the
specific assay used to measure it, although at least one
reliable assay must be available. Once qualified, the bio-
marker can be used to develop other drugs or assays
without the need to reestablish the validity of using that
biomarker in the same context of use. However, qualifi-
cation of a biomarker does not eliminate the need to sat-
isfy other regulatory requirements for use of the
biomarker test in patient care, such as an IDE for inves-
tigational use or clearance or approval for marketing.
Early consultation with the FDA about which mechan-
ism is most appropriate can help streamline the regula-
tory approval process.
Summary
Evaluation of the readiness of an omics test to be used
in clinical care or in a trial where it will guide patient
therapy requires careful consideration of the body of
evidence supporting the test’s potential clinical utility
and safety, as well as an understanding of ethical, legal,
and regulatory issues. Considerations include those relat-
ing to specimens, assays, the appropriateness of the
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omics test, the principles of clinical study design, and
regulatory, ethical, and legal issues. It is hoped that the
30-point checklist presented here will help investigators
to more reliably evaluate the quality of evidence in sup-
port of omics tests, to understand what information is
important to document about data provenance and the
test development process, and to plan appropriately for
the use of omics predictors in clinical trials or clinical
care, and that it will guide them toward the use of best
practices in omics test development. The ultimate goal
is to develop a more efficient and reliable process to
move omics assays from promising research results to
clinically useful tests that improve patient care and
outcomes.
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